Icure Pharmaceutical Incorporation (175250) — Capital Reinvestment Ratio

Latest as of June 2020: 38.07x

Icure Pharmaceutical Incorporation (175250) has a Capital Reinvestment Ratio of 38.07x as of June 2020, meaning it reinvests 38% of its operating cash flow (₩195.44 Million) in capital expenditures (₩7.44 Billion). See Icure Pharmaceutical Incorporation (175250) net asset quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

38.07x
Capex / Operating Cash Flow

Operating Cash Flow

₩195.44 Million
KRW

Capital Expenditures

₩7.44 Billion
KRW

Data as of

Jun 2020
Most recent filing

Icure Pharmaceutical Incorporation Capital Reinvestment Ratio (2017–2017)

This chart tracks Icure Pharmaceutical Incorporation's Capital Reinvestment Ratio across 1 annual periods. Check 175250 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Icure Pharmaceutical Incorporation (2017–2017)

Year-by-year Capital Reinvestment Ratio for Icure Pharmaceutical Incorporation from 2017 to 2017. For live market cap and broader valuation context, see Icure Pharmaceutical Incorporation market cap and net worth.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2017 9.02x ₩1.12 Billion ₩10.10 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow